2025/06/02

Presentation of new data from pivotal phase II clinical studies of taletrectinib, a novel ROS1 inhibitor, in patients with advanced ROS1-positive Non-Small Lung Cancer at ASCO 2025

2025/05/30

Topline Results of Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC

2025/05/08

Nippon Kayaku received MSCI ESG Ratings of AA for the second year

2025/03/03

Nippon Kayaku announces completion of marketing authorization application of a novel ROS1 inhibitor, taletrectinib, for use in patients with advanced ROS1-positive Non-Small Cell Lung Cancer in Japan

2025/01/07

Nippon Kayaku Selected as constituent of FTSE4Good Index Series, FTSE Blossom Japan Index, and FTSE Blossom Japan Sector Relative Index